On the contrary, stimulation with the TLR9 agonist did not trigger B class-switching in HIES patients with STAT3 mutations, indicating that inhibition of STAT3 might be involved in TLR9-induced B cell isotype switch. This evidence concerns the gene STAT3 and hyper-IgE syndrome.